Valuation: ImmuCell Corporation

Market Cap 9.65Cr 8.65Cr 8Cr 7.25Cr 14Cr 918.62Cr 14Cr 96Cr 38Cr 480.7Cr 36Cr 35Cr 1.53TCr P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 11Cr 9.5Cr 8.78Cr 7.95Cr 15Cr 1.01TCr 15Cr 104.97Cr 42Cr 527.48Cr 40Cr 39Cr 1.67TCr EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.73%
Yield 2024 *
-
Yield 2025 -
1 day+3.51%
1 week+0.95%
Current month+8.37%
1 month+7.49%
3 months-5.52%
6 months+27.19%
Current year+72.68%
1 week 10.19
Extreme 10.19
10.64
1 month 9.55
Extreme 9.551
10.88
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
15/04/26 Free

Chairman

11,933 0.1319%
15/04/26 Free

Director

17,899 0.1979%
15/04/26 Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
+3.51%+0.95%+72.40%+123.11% 9.32Cr
+0.50%+1.38%+57.09%+129.96% 1,14300Cr
+0.86%+5.14%+45.00%+86.15% 65TCr
-0.14%+0.42%+25.69%+105.85% 51TCr
-0.05%+1.73%+52.74%+67.74% 38TCr
-0.63%-5.97%+61.93%+37.06% 35TCr
+0.34%+1.84%+30.70%+54.27% 29TCr
-0.45%+1.19%+2.89%+26.08% 26TCr
+0.87%+3.08%+54.69%+72.74% 24TCr
+0.08%+3.67%+35.05%+107.78% 20TCr
Average +0.49%+1.40%+43.82%+81.07% 40.28TCr
Weighted average by Cap. +0.25%+1.55%+44.50%+89.02%

Financials

2024 2025
Net sales 2.65Cr 2.38Cr 2.2Cr 1.99Cr 3.72Cr 252.32Cr 3.76Cr 26Cr 10Cr 132.04Cr 9.94Cr 9.73Cr 419.16Cr 2.76Cr 2.48Cr 2.29Cr 2.08Cr 3.88Cr 263.29Cr 3.93Cr 27Cr 11Cr 137.77Cr 10Cr 10Cr 437.38Cr
Net income -21.57L -19.35L -17.89L -16.2L -30.27L -21Cr -30.63L -2.14Cr -85.19L -11Cr -80.93L -79.22L -34Cr -10.4L -9L -9L -8L -14.6L -9.91Cr -14.77L -1.03Cr -41.08L -5.18Cr -39.03L -38.2L -16Cr
Net Debt 1.13Cr 1.02Cr 94.08L 85.2L 1.59Cr 108.02Cr 1.61Cr 11Cr 4.48Cr 57Cr 4.26Cr 4.17Cr 179.44Cr 93.88L 84.23L 77.87L 70.52L 1.32Cr 89Cr 1.33Cr 9.31Cr 3.71Cr 47Cr 3.52Cr 3.45Cr 148.53Cr
Projected Income Statement - Annual - ImmuCell Corporation
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
28/26/28 $10.62 +3.51% 924
27/26/27 $10.26 +0.20% 4,167
26/26/26 $10.24 -0.10% 2,557
23/26/23 $10.25 -1.82% 11,335
22/26/22 $10.44 -0.76% 5,772
  1. Stock Market
  2. Stocks
  3. ICCC Stock